Biomedical Markers Reviewed For Bipolar and Schizophrenia
- The CoreBrain Journal Walsh Molecular Series: 3 of 4 -
Abnormalities in methylation and folate chemistry are common in schizophrenia, bipolar disorder, depression, anxiety, and certain behavioral disorders.[1]

The most common phenotype of schizophrenia involves elevated dopamine activity, and most current antipsychotic medications are aimed at lowering activity of this neurotransmitter. Unfortunately, this is the wrong approach for schizophrenics with different brain chemistry. Most efficacy experiments for depression and schizophrenia continue to involve a mixture of disorders with different brain chemistry imbalances. This blurs the data and weakens the scientific findings. Some psychiatry experts have recently urged researchers to develop objective tests for separating these illnesses into meaningful phenotypes.[1]

~ William Walsh
Agenda: The Walsh Molecular Series

* Methylation - CBJ/025 Active Link | Update CBJ/115
* Copper & Kryptopyrrole - CBJ/034 Active Link | Update CBJ/137
* Schizophrenia & Bipolar - CBJ/042 This Episode

* The End of Autism - CBJ/141 - Active

Overview

Biomedical markers, specific molecular measures, change the rules of the diagnostic and treatment game. Why? Improved target recognition for contributory molecular mind variables offers increased precision and more predictable outcomes.  It's an honor for me, and for our serious team at CoreBrain Journal, to welcome Dr. Walsh for this third in a special series of three one-hour CBJ indispensable interviews.

If you're a regular at CBJ, you will, with this CBJ/042 Episode, now understand the reason for the sequence of this Walsh three-part series. Each perspective builds on the other, and in this interview, Dr. Walsh effectively ties together connections between CBJ/025 and CBJ/034.

Why one hour for these interviews? - Because Bill's imperative message introduces fresh workable possibilities:

* Fresh, Relevant Data in a rapidly rising sea of excellent biomedical insights improves mind measurement and treatment initiatives for many who suffer from treatment failure.
* Cost Effective Measures now reveal patterns of previously under-appreciated brain functions that look on the surface as untreatable - e.g. personality disorders, autism, mood disorders, schizophrenia, cognitive deterioration, ADHD. - More biomedically precise than SPECT imaging.
* Understandable insights that lead to specific biomedical resolution strategies. Read his book. His molecular view arrives in different language packaging, and yet translates into informed, effective clinical care for many.

About Dr. Walsh and Biomedical Markers              

William J. Walsh, Ph.D., FACN, president of the non-profit Walsh Research Institute, is an internationally recognized expert in the field of nutritional medicine and a key scientist paving the way for nutrient-based psychiatry and nutritional medicine.  Over the past 30 years, Dr. Walsh has developed biochemical treatments for patients diagnosed with behavioral disorders, attention deficit (hyperactivity) disorder, autism, clinical depression, anxiety, bipolar disorders, schizophrenia, and Alzheimer’s disease that are used by doctors througho...